

Validation of the European Oncology Quality of Life Toolkit (EUonQoL-Kit).

A European cross-sectional survey.

Study protocol

OECI Oncology days, Helsinki 13<sup>th</sup> June 2024

Luana Caselli

Fondazione IRCCS Istituto Nazionale Tumori- Milano

EUonQoL - WP7 Leader INT - Coleader OECI



# The EUonQoL project





**Goal**: to develop, validate and disseminate the EUonQoL-Kit for the assessment of health-related quality of life (HRQoL) in persons with current or past cancer experience.






# The EUonQoL project



### Where we are



**EUonQoL** pilot survey

Validation of EUonQoL-Kit

#### Phase 3

Dissemination and exploitation



#### Features

- Unified HRQoL assessment tool to be used in European cancer programmes and policies
- Developed from the patients' perspective (co-design approach)
- Available in several European languages of the EU Member States and associated countries
- Electronically administered





#### **EUonQoL-Kit**



3 operational target groups

### **Features**

 Intended to assess HRQoL across the whole cancer care continuum, including people at different stages of their disease trajectory.

A	Active treatment	Undergoing or being eligible to curative or life-prolonging tumor-directed treatment			
В	Survivors	Being at least one year off treatment and being disease- free without evidence of active cancer			
С	Palliative care	Having metastatic or locally advanced disease and receiving tumor-directed treatment with palliative intent (only for symptom control) or being not eligible to any tumor-directed treatment			








### **Features**

Administered in both static and dynamic modes.



#### **Classical testing**

Fixed set of pre-selected questions presented to every respondent




#### **Computer Adaptive Testing (CAT)**


Questions automatically selected based on the respondent's answers during questionnaire completion




### Structure













### **Objectives**

#### **Primary**

 Assess validity and reliability of the EUonQoL-Kit (psychometric validation)

### **Secondary**

- Assess EUonQoL-Kit acceptability and patient burden
- Cross-validate the static and dynamic administration modes
- Explore individual factors potentially affecting HRQoL
- Explore HRQoL inequalities across European countries




## Design


 Multicentre observational cross-sectional study

45 clinical centres from 25

**EU Member States and 7** associated countries

**Coordinated by OECI** 







Design

Multicentre observational cross-sectional study

Participants will not receive any kind of intervention (pharmacological or non-pharmacological)

Only asked to fill in one or more questionnaires at a single point in time (except for the re-test, 1 hour apart)





## Eligibility criteria

#### Inclusion

- Age 18 years or more
- Present or past histologically confirmed diagnosis of solid tumor or haematological malignancy
- Being in one of the 3 conditions: A) Active treatment; B)
   Survivors; C) Palliative care
- Native tongue or fluent in the language of the questionnaire
- Written consent to the study

#### **Exclusion**

Cognitive impairment preventing questionnaire completion




## **Procedures**




Study population	Lung	Breast	Colorectal	Haematol.	Prostate	Other
	ve tment	6	6	6	6	10
patients (per CC) 30 Surv	vivors 5	5	4	4	4	8
	ative 5	5	4	4	4	8



### **Procedures**









#### **Procedures**



Where

When




How

- In pre-identified outpatient clinics and inpatient wards of each clinical centre
- 2<sup>nd</sup> half of 2024 (during specific days previously agreed with each clinical centre)
- Patient registration and data collection will be centralized through a dedicated web-platform
- Questionnaires will be administered through tablet devices via a mobile APP







- Based on the validation study results, the toolkit will be further refined and finalised.
- Different implementation strategies will be put in place to guide and disseminate the use of the tool:
- To support the core principles of EU Mission on Cancer (improving and preserving QoL)
- To complement existing health outcome measures of other EU-funded projects
- To inform evidence-based policies addressing cancer inequalities across Europe



# Thanks for your attention!



This project received funding from the European Union Horizon Europe Research and Innovation Programme Grant Agreement N. 101096362